C12N 2710/24211
Parapoxvirus
Official title: Parapoxvirus, e.g. Orf virus
C12N2710/24211 (Parapoxvirus) appears on 28 US grants and 47 published applications in this corpus.
Search patents in C12N- Granted patents
- 28
- Published applications
- 47
- Assignees
- 26
- Inventors
- 96
- Latest grant
- 5 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 2 | 6 |
| 2004 | 4 | 3 |
| 2005 | 1 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 0 | 4 |
| 2013 | 4 | 3 |
| 2014 | 3 | 2 |
| 2015 | 2 | 0 |
| 2016 | 0 | 1 |
| 2017 | 1 | 2 |
| 2018 | 0 | 2 |
| 2019 | 1 | 2 |
| 2020 | 0 | 3 |
| 2021 | 2 | 1 |
| 2022 | 1 | 2 |
| 2023 | 0 | 2 |
| 2024 | 0 | 2 |
| 2025 | 2 | 3 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/24222New viral proteins or individual genes, new structural or functional aspects ofIndexing code12
- C12N 2710/24234Use of virus or viral component as vaccineIndexing code8
- C12N 2710/24241Use of virus, viral particle or viral elements as a vectorIndexing code8
- C12N 2710/24232Use of virus as therapeutic agent, other than vaccineIndexing code7
- C12N 2710/24251Methods of production or purification of viral materialIndexing code6
- C12N 2710/24221Viruses as suchIndexing code3
- C12N 2710/24261Methods of inactivation or attenuationIndexing code2
- C12N 2710/24233Use of viral protein as therapeutic agent other than vaccineIndexing code1
Recent patents
- Recombinant pseudocowpoxvirus5 Aug 2025US 12,377,142 B2Transgene S. A.
- Oncolytic virus expressing a car T cell target and uses thereof22 Jul 2025US 12,364,724 B2City of Hope
- Recombinant Orf virus vector29 Mar 2022US 11,286,500 B2Eberhard Karls Universität Tübingen Medizinische Fakultät
- Orf virus-based platform for vaccine delivery25 May 2021US 11,013,798 B2Federal University of Santa Maria
- Method of treatment using oncolytic viruses6 Apr 2021US 10,967,015 B2New York University
- Pharmaceutical composition for treating a brain tumor23 Jul 2026US 2026/0207692 A1Patentpool Target GmbH
- Oncolytic virus expressing a car t cell target and uses thereof18 Dec 2025US 2025/0381237 A1City of Hope
- Modified parapoxvirus having increased immunogenicity2 Oct 2025US 2025/0304995 A1Prime Vector Technologies GmbH
- Mutant orf viruses and uses thereof19 Jun 2025US 2025/0197815 A9Suzhou Prajna Biotech Co., Ltd.
- Modified parapoxvirus having increased immunogenicity8 Feb 2024US 2024/0043870 A1Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
Most cited
By later US patents
- Nucleic acid and polypeptide sequences useful as adjuvants24US 6,752,995 B2Board of Regents, The University of Texas System · 2004
- Methods of treating viral infections11US 6,685,950 B2Bayer Aktiengesellschaft · 2004
- Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer10US 7,897,159 B2AiCuris GmbH & Co. KG · 2011
- Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof8US 6,541,008 B1Ludwig Institute for Cancer Research · 2003
- Parapoxviruses containing foreign DNA, their production and their use in vaccines6US 6,365,393 B1Bayer Aktiengesellschaft · 2002